![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, March 19, 2010 7:19:45 AM
07:11 AM Eastern Daylight Time, 03/19/2010 (MidnightTrader) -- A.P. Pharma (APPA:$2.06,00$0.50,0032.05%) announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting (CINV). APF530 is a long-acting formulation of granisetron utilizing the Company's proprietary Biochronomer drug delivery system.
The FDA expressed concerns relating to A.P. Pharma's two-syringe administration system. The agency identified certain deficiencies during inspections of the company's contract manufacturing facilities; it requested the company change to terminal sterilization prior to approval; and requested clarification and revision of certain analytical specifications proposed in the company's NDA.
The FDA did not request additional clinical efficacy studies, although it did ask for the re-presentation and re-analysis of select existing Phase 3 clinical trial data. The FDA requested the company perform two studies relating to bioavailability and metabolism. A.P. Pharma believes these studies should be of short duration in normal volunteers. The FDA did not accept the company's request to waive the requirement for a thorough QT study. A.P. Pharma believes this study should be of short duration in normal volunteers. The company plans to discuss the design and timing of the study with the FDA.
Price: 2.06, Change: 0, Percent Change: 0
http://www.midnighttrader.com
Recent HRTX News
- Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer • PR Newswire (US) • 09/03/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/06/2024 08:35:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:05:13 PM
- Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance • PR Newswire (US) • 08/06/2024 08:05:00 PM
- Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 • PR Newswire (US) • 07/30/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/22/2024 01:54:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/22/2024 01:44:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/22/2024 01:32:57 PM
- Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System • PR Newswire (US) • 07/15/2024 12:00:00 PM
- Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") • PR Newswire (US) • 07/02/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 08:43:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 06:21:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 01:34:07 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/31/2024 03:08:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 12:05:11 PM
- Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") • PR Newswire (US) • 05/29/2024 12:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 12:05:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:05:13 PM
- Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates • PR Newswire (US) • 05/07/2024 12:00:00 PM
- Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 • PR Newswire (US) • 04/24/2024 12:00:00 PM
- Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City • PR Newswire (US) • 04/11/2024 08:05:00 PM
- Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference • PR Newswire (US) • 03/28/2024 08:05:00 PM
- Biotech Finds Mid-Week Success Following Q4 Earnings Release • AllPennyStocks.com • 03/13/2024 08:25:00 PM
- Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates • PR Newswire (US) • 03/12/2024 08:05:00 PM
- Global Markets Await U.S. Inflation Report: Mixed Movements in Pre-Market Trading • IH Market News • 03/12/2024 11:22:57 AM
Maybacks Global and Inventel Products To Launch Global 24 Hour Shopping Channel • AHRO • Sep 3, 2024 9:15 AM
UC Asset announces plan of management stock buyback • UCASU • Sep 3, 2024 9:00 AM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM